[ad_1]
All Korean contracts are produced in domestic factories … First case of COVID-19 vaccine technology transfer
The Korea Centers for Disease Control and Prevention (KCDC) signed a contract to supply a vaccine for the novel coronavirus infection NovaVax (Corona 19) with SK Bioscience, a national manufacturer of vaccine shipments, at the headquarters of Osong, Chungbuk, at 10 a.m. M. From the 16th.
The total number of vaccines introduced by the Korean government of NovaVax is 20 million people (40 million doses), and SK Bioscience produces them all in its national factory. SK Bioscience previously signed a vaccine technology introduction contract with NovaVax.
The government will receive the NovaVax vaccine sequentially starting in the second quarter through a purchase contract with SK Bioscience.
The contract signing ceremony will be attended by Chung Eun-kyung, Director of Disease Management and Ahn Jae-yong, CEO of SK Bioscience, and James Young, President of NovaVax, will participate in a video at EE headquarters. The three parties will also discuss cooperative measures with the Korean Centers for Disease Control and Prevention regarding the production and supply of vaccines.
The NovaVax vaccine is the first COVID-19 vaccine produced in Korea through technology transfer.
The Agency for Disease Control said, “The technology transfer will not only help secure the original technology for vaccine development in Korea, but will also serve as an opportunity to establish a stable vaccine supply base.”
The NovaVax vaccine was developed using a synthetic antigen method used for vaccination against influenza or hepatitis B.
This is different from previous government contracts for the Pfizer-Modena (mRNA) and AstraZeneca-Jansen (viral vector) vaccines.
Synthetic antigenic vaccine is a method that induces an immune response by synthesizing antigenic proteins and administering them to the human body by mixing them with an adjuvant. It has a long development history and is highly safe and can be stored and distributed between 2 and 8 ° CC. Shelf life is 2 to 3 years. As long as
“NovaVax vaccine, which can be produced and supplied in Korea, will contribute to the stable supply and supply of vaccines in Korea in the face of growing uncertainty in vaccine supply around the world.” 2 million doses of vaccine were obtained, and we will continue to strive for an early supply and prompt vaccination. “
Yunhap news
[ad_2]
